New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Today’s treatment for myeloma is shifting to the use of novel targeted therapy, or the use of drugs and their combinations to “target specific aspects of the biology of tumor cells.” In this report, the IMWG looks at the” biological rationale for the use of the most important new agents for treating multiple myeloma and summarizes their clinical activity.”

Discussed are

  • Data from approved and active agents (including second- and third-generation proteasome inhibitors (PIs), immunomodulatory agents, and alkylating agents).
  • “Agents with novel mechanisms of action, such as monoclonal antibodies (MoAbs), cell cycle-specific drugs, deacetylase inhibitors, agents acting on the unfolded protein response, signaling transduction pathway inhibitors and kinase inhibitors”

New agents or mechanisms showing promise include:

  • anti-CD38 MoAb, such as daratumumab
  • immunotherapy in combination of the anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone, which has produced exciting results in the relapsed/refractory setting


Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF

Click here to view article:

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.